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Background: Updating is important to ensure clinical guideline (CG) recommendations remain valid. However, little
research has been undertaken in this field. We assessed CGs produced by the National Institute for Health and Care
Excellence (NICE) to identify and describe updated recommendations and to investigate potential factors associated
with updating. Also, we evaluated the reporting and presentation of recommendation changes.
Methods: We performed a descriptive analysis of original and updated CGs and recommendations, and an assessment
of presentation formats and methods for recording information. We conducted a case-control study, defining cases as
original recommendations that were updated (‘new-replaced’ recommendations), and controls as original recommendations
that were considered to remain valid (‘not changed’ recommendations). We performed a comparison of main
characteristics between cases and controls, and we planned a multiple regression analysis to identify potential
predictive factors for updating.
Results: We included nine updated CGs (1,306 recommendations) and their corresponding original versions
(1,106 recommendations). Updated CGs included 812 (62%) recommendations ‘not reviewed’, 368 (28.1%) ‘new’
recommendations, 104 (7.9%) ‘amended’ recommendations, and 25 (1.9%) recommendations reviewed but
unchanged. The presentation formats used to indicate the changes in recommendations varied widely across
CGs. Changes in ‘amended’, ‘deleted’, and ‘new-replaced’ recommendations (n = 296) were reported infrequently,
mostly in appendices. These changes were recorded in 167 (56.4%) recommendations; and were explained in 81
(27.4%) recommendations. We retrieved a total of 7.1% (n = 78) case recommendations (‘new-replaced’) and 2.4%
(n = 27) control recommendations (‘not changed’) in original CGs. The updates were mainly from ‘Fertility CG’,
about ‘gynaecology, pregnancy and birth’ topic, and ‘treatment’ or ‘prevention’ purposes. We did not perform the
multiple regression analysis as originally planned due to the small sample of recommendations retrieved.
Conclusion: Our study is the first to describe and assess updated CGs and recommendations from a national
guideline program. Our results highlight the pressing need to standardise the reporting and presentation of
updated recommendations and the research gap about the optimal way to present updates to guideline users.
Furthermore, there is a need to investigate updating predictive factors.
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Clinical Guidelines (CGs) are ‘statements that include
recommendations intended to optimize patient care, that
are informed by systematic reviews of evidence and an
assessment of the benefits and harms of alternative care
options’ [1]. Scientific knowledge is in constant change,
and new information requires frequent assessment to
determine whether it changes clinical practice. There-
fore, CGs require a periodic review of new scientific
research that may change the influencing factors in the
formulation of their recommendations (quality of the
evidence, balance between benefits and harms, patients’
values and preferences, or resource use and cost [2]).
Any decision to update a guideline must balance the
need to reflect changes in the evidence against the need
for stability, because frequent changes to guideline
recommendations would make implementation difficult
[3-6]. Furthermore, a requirement to maintain a clinically
relevant library of guidelines and the resource use this
requires may also be a deciding factor.
Updating CGs is a complex process and includes three
main stages: identifying important new evidence; asses-
sing if the new evidence has an impact on the current
guideline recommendations and whether an update is
required; and the updating process [7]. Some research
has been published about the identification and assess-
ment of new evidence (encompassed sometimes as
review, surveillance or monitoring process), [8,9]. Less
attention has been paid to the process of updating CGs
per se, making the assumption that it is similar to the
development process [7,8].
The role of the National Institute for Health and Care
Excellence (NICE) is to improve outcomes for people
using the National Health Service in England and Wales
and other public health and social care services. Since
2005, NICE has developed CGs which are systematically-
developed statements to assist professional and patient
decisions about appropriate care for specific clinical
circumstances. As advances in medicines and technologies
may lead to guideline recommendations becoming obso-
lete, CGs developed by NICE are published with the
expectation that they will be regularly reviewed and
updated as necessary [3].
These processes have evolved in different versions of
NICE manuals [3-5]. At present, NICE has suspended
the routine review process every three years and an
interim surveillance programme is being implemented,
which alternates rapid (two, six, and ten years after
publication) or full reviews (four and eight years after
publication) [6]. Also, rapid updates of guidelines are
being piloted [10].
Although the updating process is not yet standardised,
some institutions try to keep their CG program up to
date [11]. An analysis of current practice would providerelevant information about CG review and update
process, and also highlight existing gaps in the process.
For example, the identification of recommendations
with high or low turnover or clinical questions with a
greater proportion of updated recommendations will
help to focus evidence surveillance systems and, conse-
quently, will improve the distribution of resources in
the CG updating process.
Therefore, we evaluated updated CGs from NICE to
identify and describe updated recommendations and to
investigate factors associated with updating (predictive
factors). Also, we assessed presentation formats and
methods for recording information when presenting the
changes from the original to updated recommendations.
Methods
Study design
We performed a descriptive study of original and up-
dated CGs and recommendations. Also, we conducted
a case-control study to identify potential predictive factors
for updating.
Setting and participants
We included all updated CGs from NICE; and their
corresponding original version. We included an updated
CG if: it was partially updated; it was the first updated
version of the original; it included the updating status
of each recommendation; and it was published on the
NICE website up to May 2013. Updated CGs were ob-
tained from the NICE website in May 2013 by searching
the list of published CGs (http://guidance.nice.org.uk/
CG/Published). After we obtained the sample of the
updated CGs, we retrieved the originals from internal
sources within NICE as the original versions of the CGs
are no longer available on the website.
Finally we reviewed CGs and selected the recommenda-
tions. We included all the recommendations from both
original and updated CGs, except research recommenda-
tions because these are unanswered research questions or
areas of uncertainty that emerge during guidance develop-
ment as opposed to recommendations for clinical practice.
We defined cases as original recommendations that were
updated (‘new-replaced’ recommendations), and controls as
original recommendations that were still valid after an
updating process (‘not changed’ recommendations).
Variables and data sources
We mapped original and updated CGs and extracted the
following metrics: publication date, topic area (using NICE
taxonomy), and guideline development centre (centres
that are contracted to develop the guidelines on behalf of
NICE). We also extracted from the updated CGs the infor-
mation about update status labels and definitions (Table 1).
We mapped the corresponding original recommendations
Table 1 Update status labels and definitions




Recommendation from original guideline that has been changed following
review of evidence.
Cases
New-added New recommendation following review of evidence.
Not changed
Recommendation from the original guideline where evidence has been
reviewed but the recommendation is not changed.
Controls
Deleted Recommendation from original guideline that has been removed.
Not reviewed
Recommendation from the original guideline where the evidence has not
been formally reviewed for the update.
Amended
A small amendment has been made to the original recommendation but the
evidence has not been updated or reviewed.
*Adapted from NICE manual [5].
Martínez García et al. Implementation Science 2014, 9:72 Page 3 of 9
http://www.implementationscience.com/content/9/1/72and extracted: recommendations, heading and subhead-
ing, and their strength (with SIGN or GRADE system
[2,12]). We coded the recommendations by: CG topic
area, years between versions, purpose (using key words),
and strength [Additional file 1].
We mapped and recoded the updated recommen-
dations and extracted similar information plus: update
status (Table 1); change recorded (whether changes in
the recommendations were registered) [Additional file 1]
and justification of the change. For example, the rec-
ommendation in Fertility CG 2004 [13], ‘Women who
are undergoing in vitro fertilisation treatment using
gonadotrophin-releasing hormone agonists for pituitary
down regulation should be informed that luteal support
using human chorionic gonadotrophin or progesterone
improves pregnancy rates’; was replaced in Fertility CG
2013 [14] with ‘Offer women progesterone for luteal phase
support after in vitro fertilisation treatment’; the change
was recorded in the guideline as ‘new 2013′ label; and the
change was justified as follows ‘New evidence shows that
only progesterone is useful as a luteal phase support, so
the recommendation has been changed’.
We matched original and updated recommendations;
firstly using the changes recorded in the updated CGs,
and secondly matched recommendation with recom-
mendation, to obtain the updating status. One reviewer
mapped, extracted, and recoded the data. A second
evaluator checked the coding and the link processes.
Data analysis
We performed a descriptive analysis of included CGs
and recommendations and calculated absolute and
relative frequencies (purpose of recommendations and
update status) or median and range (number of recom-
mendations per CG and time between versions of original
and updated CGs), as appropriate. We also conducted a
descriptive analysis of the update status of recommenda-
tions, changes recorded and justification for the change.
We assessed the reported information about the change inrecommendations per CG based on seven issues (record-
ing information score): recommendation update status
defined; changes recorded for ‘amended’ recommenda-
tions; changes explained for ‘amended’ recommendations;
changes recorded for ‘deleted’ recommendations; changes
explained for ‘deleted’ recommendations; changes re-
corded for ‘new-replaced’ recommendations; and changes
explained for ‘new-replaced’ recommendations. For each of
the seven issues the selection was one (yes) or zero (no),
and the summation was the numerator. The maximum
points score were seven (denominator), but depended on
the type of update status included in CGs (for example,
lung cancer CG 2011 [15] did not have ‘amended’ or ‘new’
recommendations so the denominator was three). The final
score was reported on a scale of ten (sum points obtained/
highest score possible * 10 = final score).
We compared cases (‘new-replaced’) and controls (‘not
changed’) recommendations using Pearson chi-square test
(for categorical variables) or Mann-Whitney U test (for quan-
titative variables), as appropriate. We planned to perform a
multiple regression analysis with variables associated with up-
dating in bivariate analysis and with relevant variables agreed
by the research group [16]. In addition, we aimed to link rec-
ommendations with references supporting them with a view
to exploring the association between number of references
linked per recommendation and its vulnerability to change.
We accepted p value ≤0.05 as significant in all calcula-
tions. We performed the analysis with SPSS 15.0 (SPSS
Inc., Chicago, Illinois, United States).
Results
Included CGs and recommendations
We retrieved 21 (12.7%) updated CGs out of a total of
166 current CGs (Figure 1); and linked them with 24
original CGs (three CGs about type 2 diabetes were
merged into one during an update). We excluded 12
updated CGs: eight were not reported as partial update,
and four did not record the update status of each recom-
mendation (Additional file 2). Finally, we included nine
Figure 1 Flow diagram of included clinical guidelines. Abbreviations: CG: Clinical guideline. *Accessed 15 May, 2013. #Four OriginalCGs about
Type 2 diabetes were updated in one UpdatedCG.
Martínez García et al. Implementation Science 2014, 9:72 Page 4 of 9
http://www.implementationscience.com/content/9/1/72updated CGs and their corresponding original CGs
(Table 2) [13-15,17-31]. Of the study sample, original CGs
were published from 2003 to 2006; and updated CGs were
published from 2007 to 2013 [Table 2]. The median time
between versions was 7.2 years (range 4.3 – 9.0).
Original CGs included a median of 99 recommenda-
tions per CG (range 50 – 220), and 126 (range 52 – 285)
for updated CGs (Table 3). The majority of recommenda-
tions across all CGs were about ‘gynaecology, pregnancy
and birth’ (24.9% of original recommendations and 25.7%
of updated recommendations) or ‘respiratory’ topics
(25.9% of original recommendations and 23.8% of updated
recommendations); were most commonly related to ‘treat-
ment’ purpose or ‘supporting patients or carers’ (27.9%
and 19.2% of original recommendations and 28.4% and
18.3% of updated recommendations respectively); and
most were graded as ‘D’ or as ‘weak’ recommendations
(39.8% of original recommendations and 42.7% of updated
recommendations) (Table 3). The references from recom-
mendations to evidence could not be retrieved.
Recommendations updating status
Updated CGs included 812 (62%) recommendations ‘not
reviewed’; 368 (28.1%) ‘new’ recommendations (‘new-
added’ and ‘new-replaced’); 104 (7.9%) ‘amended’ recom-
mendations; and 25 (1.9%) recommendations that were
reviewed but remained unchanged (Table 3).
‘Reviewed’ recommendations (‘new’ plus ‘not changed’;
393, 30%) were included in 45 sections of the CGs with
recommendations (61.6%).‘New’ recommendations were mainly ‘new-added’ (294,
79.9%), from ‘gynaecology, pregnancy and birth’ topic
(115, 31.3%), had a ‘treatment’ purpose (146, 39.7%), and
were graded as ‘weak’ (308, 83.7%). The main reasons for
the changes in the ‘new-replaced’ were the identification
of new evidence (21/33; 63.6%) and changes in writing
style (11/33; 33.3%) (Additional file 3).
Presentation formats and information recording
The presentation formats used to indicate the changes
in recommendations or sections varied across updated
CGs. Five (5/9, 55.6%) updated CGs used update status
labels for recommendations plus highlight colour
[25,26,28,30,31]; three (3/9; 33.3%) used update status
labels for recommendations plus a bar down the side
of the page [15,29,14]; and one (1/9; 11.1%) only indi-
cated the recommendations’ update status [27]. Updat-
ing status labels were defined in seven CGs (77.8%)
[14,15,25,27,29-31] (definitions are available in Additional
file 4).
The updated CGs with highest recording information
score were for those that included a head to head com-
parison between original and updated recommendations
in an appendix (10 points for both Caesarean section
CG – 2011 [29] and Fertility CG – 2013 [14]); and the
lowest scores were for the oldest updates (1.4 points for
Head injury CG – 2007 [25] and 2.9 points for Chronic
heart failure CG - 2010 [27]). An illustration of presenta-
tion formats is available in Additional file 5 and scores
are available in Additional file 6.
Table 2 Included clinical guidelines
Original clinical guidelines Updated clinical guidelines






- Anaemia management in
chronic kidney disease (CG39)
(replaced by CG114) [24]
NCC-CC Sep-06 - Anaemia management in
people with chronic kidney
disease (CG114) [28]
NCGC Feb-11
- Caesarean section (CG13)
(replaced by CG132) [21]
NCC-WCH Apr-04 - Caesarean section (CG132) [29] NCC-WCH Nov-11
- Chronic heart failure (CG5)
(replaced by CG108) [19]
NCC-CC Jul-03 - Chronic heart failure (CG108) [27] NCGC-ACC Aug-10
- Chronic obstructive pulmonary
disease (CG12) (replaced by
CG101) [20]
NCC-CC Feb-04 - Chronic obstructive pulmonary
disease (updated) (CG101) [26]
NCGC-ACC Jun-10
- Epilepsy (CG20) (replaced by
CG137) [22]
NCC-PC Oct-04 - Epilepsy (CG137) [30] NCGC-ACC Jan-12
- Fertility (CG11) (replaced by
CG156) [13]
NCC-WCH Feb-04 - Fertility (CG156) [14] NCC-WCH Feb-13
- Head injury (CG4) (replaced
by CG56) (withdrawn) [18]
NCC-AC Jun-03 - Head injury (CG56) [25] NCC-AC Sep-07
- Infection control (CG2)
(replaced by CG139) [17]
National Collaborating Centre for
Nursing & Supportive Care and
Thames Valley University
Jun-03 - Infection control (CG139) [31] NCGC-ACC Mar-12
- Lung cancer (CG24) (replaced
by CG121) [23]
NCC-AC Feb-05 - Lung cancer (CG121) [15] NCC-C Apr-11
Abbreviations: NCC-AC National Collaborating Centre for Acute Care, NCC-C National Collaborating Centre for Cancer, NCC-CC National Collaborating Centre for
Chronic Conditions, NCC-PC National Collaborating Centre for Primary Care, NCC-WCH National Collaborating Centre for Women and Children’s Health, NCGC
National Clinical Guideline Centre, NCGC-ACC National Clinical Guideline Centre for Acute and Chronic Conditions.
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ported frequently in updated CGs appendices (n = 7;
77.8%) (Additional file 4). The changes in ‘amended’ , ‘de-
leted’ and ‘new-replaced’ recommendations (n = 296)
were recorded in 167 (56.4%) recommendations; and
were explained in 81 (27.4%) recommendations. The
most common change factor in ‘amended’ recommenda-
tions was ‘change in writing style (accuracy, clarity,
consistency, or terminology)’ (n = 23, 65.7%), in ‘deleted’
recommendations was ‘recommendation outside the
scope’ (n = 4; 30.8%); and in ‘new-replaced’ recommen-
dations was ‘incorporation of new evidence’ (n = 21;
63.6%) (Additional file 3).
Predictive factors for updating
After the linking process, we identified in original CGs:
229 (20.7%) ‘reviewed’ (‘deleted’ plus ‘new-replaced’ plus
‘not changed’), 783 (70.8%) ‘not reviewed’ and 94
(8.5)‘amended’ recommendations [Table 3]. A total of
7.1% (n = 78) had been ‘new-replaced’ (cases) and 2.4%
(n = 27) were ‘not changed’ (controls) recommendations.
More than one updated recommendation could corres-
pond to one original recommendation and vice versa.
For this reason, the absolute overall numbers of update
status do not match between versions (Table 2).
There were differences between ‘new-replaced’ (cases)
versus ‘not changed’ (controls) recommendations by CGs,topic and purpose, but not by time between publication
versions or strength of recommendations (Table 4).
The ‘new-replaced’ recommendations (cases) were
mainly from ‘Fertility (CG11) 2004′ CG [13], about ‘gy-
naecology, pregnancy and birth’ topic, and ‘treatment’ or
‘prevention’ purposes [Table 4].
We considered the sample of 105 recommendations
inadequate to perform a multiple regression analysis [16].
Discussion
Our study evaluated a cohort of updated recommenda-
tions in one of the leading national CG development
programs. We identified 368 (28.1%) ‘new’ recommenda-
tions in the updated CGs; of these, 7.1% (78/1106) being
‘new-replaced’ recommendations from the original CGs.
The changes were mainly due to the identification of
new evidence and were topic and purpose related.
We included in the study partially updated guidelines;
defined as CGs that include some recommendations that
required updating in the light of new evidence, or be-
cause they were unclear [4]. The reason to include only
partial updates is that in full updates there is no infor-
mation about the modifications made with respect to
the previous versions. Inclusion of only partial updates
resulted in the majority of original recommendations
not being reviewed. In some instances updated CGs
can have the same original scope (no new areas were





(n = 1106) (n = 1309)
CGs, n (%)
- Anaemia management in
chronic kidney disease
50 (4.5) 52 (4.0)
- Caesarean section 108 (9.8) 124 (9.5)
- Chronic heart failure 92 (8.3) 95 (7.3)
- Chronic obstructive
pulmonary disease
193 (17.5) 182 (13.9)
- Epilepsy 220 (19.9) 285 (21.8)
- Fertility 167 (15.1) 213 (16.3)
- Head injury 83 (7.5) 126 (9.6)
- Infection control 99 (9.0) 102 (7.8)
- Lung cancer 94 (8.5) 130 (9.9)
CGs topic, n (%)
- Blood and immune system/
Urogenital
50 (4.5) 52 (4.0)
- Cardiovascular 92 (8.3) 95 (7.3)
- Central nervous system 220 (19.9) 285 (21.8)
- Gynaecology, pregnancy
and birth
275 (24.9) 337 (25.7)
- Injuries, accidents and
wounds
83 (7.5) 126 (9.6)
- Public health 99 (9.0) 102 (7.8)
- Respiratory 287 (25.9) 312 (23.8)
Recommendations purpose, n (%)
- Access to services - Referral
and approach to care - Service
organisation
168 (15.2) 226 (17.3)
- Diagnostic 188 (17.0) 223 (17.0)
- Monitoring - Follow up 64 (5.8) 68 (5.2)
- Prevention practices 153 (13.8) 164 (12.5)
- Supporting patients and
carers
212 (19.2) 239 (18.3)
- Treatment 309 (27.9) 372 (28.4)
- >1 purpose or others 12 (1.1) 17 (1.3)
Recommendations strength - SIGN, n (%)
- A 194 (17.5) 133 (14.1)
- B 98 (8.9) 87 (9.2)
- C 140 (12.7) 118 (12.5)
- D 440 (39.8) 402 (42.7)
- GPP 214 (19.3) 187 (19.9)
- Others 20 (1.8) 14 (1.5)
Recommendations strength - GRADE, n (%)
- Legal - - 11 (3.0)
- Strong - - 49 (13.3)
- Weak - - 308 (83.7)
Table 3 Recommendations characteristics (Continued)
Update status, n (%)
- Amended 94 (8.5) 104 (7.9)
- Deleted 124 (11.2) - -
- New – added - - 294 (22.5)
- New – replaced 78 (7.1) 74 (5.7)
- Not changed 27 (2.4) 25 (1.9)
- Not reviewed 783 (70.8) 812 (62.0)
Abbreviations: CG Clinical guidelines, GPP Good practice point.
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new key areas were identified) [4]. We did not assess the
differences in scopes or included clinical questions be-
tween guidelines versions. It would have been useful for
the analysis that all updated CGs recorded these issues.
Only a minority of updated CGs included appendices
highlighting how recommendations had changed between
versions of the CG. Similarly there was no information
reported about the methods undertaken for the review,
surveillance or monitoring process.
The identification of the updated CGs was sometimes
difficult because occasionally two or more CGs were
merged, titles were modified, and some guidelines had
went through more than one updating process. The ex-
pected increase of guideline updates in the future makes
it necessary to improve labelling to avoid confusion.
To further complicate the analysis, access to the ori-
ginal version of the CG was not straightforward, as
they had been removed from the website. Nevertheless,
we managed in all cases to obtain the original CGs as
copies of the original guidelines are stored internally
within NICE.
There was not a prioritisation for updating particular
sections of the included CGs, hence, the distribution of
reviewed recommendations was from across all guide-
lines and sections.
The proportion of 28.1% (368) ‘new’ recommendation
over a median time frame of seven years since their de-
velopment is similar to a recent survival analysis of the
validity of recommendations (22.1 % recommendations
were considered to need a potential update, median time
frame of four years) [32]. A standardised process for
conducting surveillance reviews every three years was
introduced in August 2010 therefore; the median time
frame of seven years between versions of CGs included
in this study may be attributed partly because these CGs
were reviewed for update on an ad hoc basis.
We observed unclear definition about update status
labels, variability in the presentation formats for recom-
mendation changes and poor reporting for the justifica-
tion for change. Only two CGs included an appendix
with a detailed comparison of the original and updated
recommendations [14,29]. There is scant research in these











1 (1.3) - -
0.036
- Caesarean section 10 (12.8) 1 (3.7)
- Chronic heart failure 4 (5.1) 4 (14.8)
- Chronic obstructive
pulmonary disease
- - - -
- Epilepsy 2 (2.6) 5 (18.5)
- Fertility 34 (43.6) 10 (37.0)
- Head injury 3 (3.8) - -
- Infection control 24 (30.8) 7 (25.9)
- Lung cancer - - - -
Time between publication versions, median (range)
- Years 8.8 (4.3-9.0) 8.8 (7.1-9.0) 0.296
CGs topic, n (%)
- Blood and immune
system/Urogenital
1 (1.3) - -
0.027
- Cardiovascular 4 (5.1) 4 (14.8)
- Central nervous
system
2 (2.6) 5 (18.5)
- Gynaecology,
pregnancy and birth
44 (56.4) 11 (40.7)
- Injuries, accidents
and wounds
3 (3.8) - -
- Public health 24 (30.8) 7 (25.9)
- Respiratory - - - -
Recommendations purpose, n (%)
- Access to services -
Referral and approach
to care - Service
organisation
3 (3.8) 2 (7.4)
0.027
- Diagnostic 7 (9.0) 1 (3.7)
- Monitoring - Follow up 1 (1.3) 5 (18.5)
- Prevention practices 23 (29.5) 7 (25.9)
- Supporting patients
and carers
17 (21.8) 2 (7.4)
- Treatment 23 (29.5) 9 (33.3)
- >1 procedure - Others 4 (5.1) 1 (3.7)
Recommendations strength - SIGN, n (%)
- A 25 (32.1) 6 (22.2)
0.296
- B 5 (6.4) 2 (7.4)
- C 11 (14.1) 5 (18.5)
- D 19 (24.4) 7 (25.9)
- GPP 16 (20.5) 6 (22.2)
- Others 2 (2.6) 1 (3.7)
Abbreviations: CG Clinical guidelines, GPP Good practice point.
aPearson Chi-Square or Mann-Whitney Test, as appropriate.
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ginal recommendations or in the field of systematic re-
views [33-35].
An important area to highlight is the coexistence of
two systems of strength of recommendations in the
same updated CG. This is due to the relatively recent
decision to move from the SIGN system to GRADE to
rate the quality of the evidence and formulate the
recommendations. At the moment, the impact of this
potential confusion for users is unknown.Strengths and limitations
Our study has several strengths. First, we followed a
structured and rigorous approach and developed a
protocol that is available from the authors. Second, we
explored all CGs from a national program that has a
well-established reviewing and updating process. Finally,
we explored several issues that have not been assessed until
now (e.g., updating reporting and presentation formats and
predictive factors for updating recommendations).
Our study also has some limitations. We were not able
to link recommendations with references supporting
them, as originally planned. This could have led us to
explore the association between number of references
linked per recommendation and its vulnerability to
change [35]. Furthermore, the identification of indi-
vidual recommendations was difficult because, for
example, more than one updated recommendation
could correspond to an original recommendation, and
vice versa. We might have therefore underestimated
the real proportion of recommendations that were
changed. Although the results suggest there were
differences between changed versus not changed rec-
ommendations by CGs, topic and purpose, it was not
possible to define predictive factors for updating rec-
ommendations. Additional work is needed to define
changes to CG recommendations because this will help
to focus evidence surveillance systems and, conse-
quently, will improve the distribution of resources in
the CG updating process. Finally, we only included the
first update of each guideline and excluded later
versions if available.Implications of our results for practice and research
Our study is the first to describe and assess updated
CGs and recommendations from a national guideline
program. Our results highlight the pressing need to
standardise the reporting and presentation of updated
recommendations. We have also identified a research
gap about the optimal way to present updates to the
users. Furthermore, there is a need for larger studies to
investigate updating predictive factors.
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listed the documented changes by type of recommendation (amended,
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explained by CGs.
Additional file 5: Presentation formats examples. We captured
images form included updated clinical guidelines to illustrate different
presentation formats.
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